{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:53:52Z","timestamp":1790297632950,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.rpth.2022.100018","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T12:52:22Z","timestamp":1672923142000},"page":"100018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Thrombin generation and implications for hemophilia therapies: A narrative review"],"prefix":"10.1016","volume":"7","author":[{"suffix":"Jr","given":"Robert F.","family":"Sidonio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureane","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Dargaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2022.100018_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.05.006","article-title":"The central role of thrombin in bleeding disorders","volume":"38","author":"Negrier","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2022.100018_bib2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2022.100018_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1160\/TH04-10-0706","article-title":"Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B","volume":"93","author":"Dargaud","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2020.102416","article-title":"Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: effects of bypassing agents and antithrombin reduction","volume":"82","author":"Livnat","year":"2020","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.rpth.2022.100018_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/hae.13411","article-title":"A\u00a0golden age for haemophilia treatment?","volume":"24","author":"Makris","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"Polderdijk","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2022.100018_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0192623310389474","article-title":"Continuing education course #2: current understanding of hemostasis","volume":"39","author":"Gale","year":"2011","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.rpth.2022.100018_bib8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A\u00a0cell-based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/B:THRO.0000014588.95061.28","article-title":"Remodeling the blood coagulation cascade","volume":"16","author":"Hoffman","year":"2003","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2022.100018_bib10","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation","volume":"22","author":"Monroe","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2022.100018_bib11","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1046\/j.1538-7836.2003.00298.x","article-title":"What is all that thrombin for?","volume":"1","author":"Mann","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jth.12217","article-title":"The transition of prothrombin to thrombin","volume":"11","author":"Krishnaswamy","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1538-7836.2007.02500.x","article-title":"The central role of thrombin in hemostasis","volume":"5","author":"Crawley","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2006.11.001","article-title":"Thrombin generation and fibrin clot structure","volume":"21","author":"Wolberg","year":"2007","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2022.100018_bib15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ajh.20963","article-title":"The impact of major surgery on blood coagulation factors and thrombin generation","volume":"82","author":"Horne","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2022.100018_bib16","first-page":"207","article-title":"Optimal management of hemophilic arthropathy and hematomas","volume":"5","author":"Lobet","year":"2014","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.rpth.2022.100018_bib17","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2516.2009.01994.x","article-title":"Thrombin generation and bleeding in haemophilia A","volume":"15","author":"Brummel-Ziedins","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2516.2008.01877.x","article-title":"Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?","volume":"15","author":"Salvagno","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib19","first-page":"9","article-title":"Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay","volume":"7","author":"Ghosh","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2008-1066024","article-title":"The phenotypic heterogeneity of severe hemophilia","volume":"34","author":"Jayandharan","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2022.100018_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1309\/6A8UURH9NU2YNFBP","article-title":"Reduced clinical severity in a mutationally well-characterized cohort of severe hemophilia with associated thrombophilia","volume":"130","author":"Shetty","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.rpth.2022.100018_bib22","first-page":"314","article-title":"Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future","volume":"12","author":"Jim\u00e9nez-Yuste","year":"2014","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2022.100018_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bjhh.2017.03.009","article-title":"Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations","volume":"39","author":"Duarte","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.rpth.2022.100018_bib24","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1160\/TH09-10-0732","article-title":"Heterozygous antithrombin deficiency improves in\u00a0vivo haemostasis in factor VIII-deficient mice","volume":"103","author":"Bolliger","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2516.2008.01737.x","article-title":"New assays for monitoring haemophilia treatment","volume":"14","author":"Shima","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib26","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1111\/jth.15538","article-title":"Clinical use of thrombin generation assays","volume":"19","author":"Binder","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-13-1","article-title":"A\u00a0general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis","volume":"13","author":"Lanc\u00e9","year":"2015","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2022.100018_bib28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MBC.0b013e328355111f","article-title":"Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?","volume":"23","author":"Campo","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2022.100018_bib29","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Dargaud","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.tmrv.2009.09.004","article-title":"Correction of coagulation in dilutional coagulopathy: use of kinetic and capacitive coagulation assays to improve hemostasis","volume":"24","author":"Schols","year":"2010","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.rpth.2022.100018_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2516.2006.01345.x","article-title":"Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A","volume":"12","author":"Goldenberg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/jcp.6.1.3","article-title":"A\u00a0thrombin generation test; the application in haemophilia and thrombocytopenia","volume":"6","author":"Macfarlane","year":"1953","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.rpth.2022.100018_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.rpth.2022.100018_bib34","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"Depasse","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib35","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3324\/haematol.2020.253047","article-title":"Thrombin generation: a global coagulation procedure to investigate hypo- and hyper-coagulability","volume":"105","author":"Tripodi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2022.100018_bib36","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1182\/blood-2012-08-378935","article-title":"Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives","volume":"121","author":"Young","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2022.100018_bib37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1538-7836.2010.03767.x","article-title":"Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile","volume":"8","author":"Santagostino","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/hae.13493","article-title":"Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq(R) (human-cl rhFVIII) in previously treated patients with severe haemophilia A","volume":"24","author":"Dargaud","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2005.05612.x","article-title":"The measurement and application of thrombin generation","volume":"130","author":"Baglin","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2022.100018_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1538-7933.2003.00576.x","article-title":"Thrombin generation: phenotypic quantitation","volume":"2","author":"Brummel-Ziedins","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.blre.2019.03.002","article-title":"Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis","volume":"35","author":"Bannow","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2022.100018_bib42","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/hae.13539","article-title":"Prediction of individual factor VIII or IX level for the correction of thrombin generation in haemophilic patients","volume":"24","author":"Chelle","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619836171","article-title":"Evaluation of global hemostatic assays in response to factor VIII inhibitors","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2022.100018_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000071637","article-title":"Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay","volume":"33","author":"Turecek","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.rpth.2022.100018_bib45","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1182\/blood-2010-06-291906","article-title":"Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery","volume":"116","author":"Dargaud","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2022.100018_bib46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/rth2.12295","article-title":"Global coagulation assays in hemophilia A: a comparison to conventional assays","volume":"4","author":"Aghighi","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib47","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: new challenges","volume":"4","author":"Lenting","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2022.100018_bib48","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et\u00a0al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020;26:1\u2013158.","DOI":"10.1111\/hae.14046"},{"key":"10.1016\/j.rpth.2022.100018_bib49","series-title":"Safety of FEIBA and Emicizumab (SAFE): dose escalation study evaluating the safety of in\u00a0vivo administration of activated prothrombin complex concentrate in hemophilia A patients with inhibitors on emicizumab","author":"Kizilocak","year":"2021"},{"key":"10.1016\/j.rpth.2022.100018_bib50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.25319","article-title":"Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia","volume":"94","author":"Ramiz","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2022.100018_bib51","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3324\/haematol.2019.242735","article-title":"Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies","volume":"105","author":"Peyvandi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2022.100018_bib52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib53","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1111\/jth.15106","article-title":"Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation","volume":"18","author":"Valke","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2022.100018_bib55","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2022.100018_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5045\/br.2018.53.1.41","article-title":"Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX","volume":"53","author":"Yoo","year":"2018","journal-title":"Blood Res"},{"key":"10.1016\/j.rpth.2022.100018_bib57","first-page":"344","article-title":"Diagnosis and treatment of hemophilia","volume":"17","author":"Kizilocak","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.rpth.2022.100018_bib58","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1373\/clinchem.2015.248625","article-title":"Thrombin generation assay and its application in the clinical laboratory","volume":"62","author":"Tripodi","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.rpth.2022.100018_bib59","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"Polderdijk","year":"2017","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.rpth.2022.100018_bib60","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2022.100018_bib61","first-page":"457","article-title":"Non-factor replacement therapy for haemophilia: a current update","volume":"16","author":"Franchini","year":"2018","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2022.100018_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048172","article-title":"Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition","volume":"7","author":"Doshi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2022.100018_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2022.100018_bib64","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/hae.12309","article-title":"Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors","volume":"20","author":"Luna-Z\u00e1izar","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib65","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2141.2010.08378.x","article-title":"Combination of FVIII and by-passing agent potentiates in\u00a0vitro thrombin production in haemophilia A inhibitor plasma","volume":"151","author":"Klintman","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2022.100018_bib66","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1365-2516.2008.01688.x","article-title":"Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma","volume":"14","author":"Livnat","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib67","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"Hoffman","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib68","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2022.100018_bib69","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2022.100018_bib70","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jth.15682","article-title":"A\u00a0novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys","volume":"20","author":"Lauritzen","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2022.100018_bib72","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-155018","article-title":"Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia: first results from a phase 3 study to evaluate efficacy and safety in people with hemophilia A or B without inhibitors (ATLAS-A\/B)","volume":"138","author":"Srivastava","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2022.100018_bib73","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2021-150273","article-title":"Efficacy and safety of fitusiran prophylaxis, an siRNA therapeutic, in a multicenter phase 3 study (ATLAS-INH) in people with hemophilia A or B, with inhibitors (PwHI)","volume":"138","author":"Young","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2022.100018_bib74","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5482\/20170004","article-title":"Thromboembolic risks of non-factor replacement therapies in hemophilia","volume":"37","author":"Tiede","year":"2017","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2022.100018_bib75","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1182\/bloodadvances.2021004802C","article-title":"Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding","volume":"5","author":"Hoffman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2022.100018_bib76","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2141.2008.07267.x","article-title":"Thrombin generation testing in routine clinical practice: are we there yet?","volume":"142","author":"van Veen","year":"2008","journal-title":"Br J Haematol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922022683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922022683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:23:28Z","timestamp":1762863808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922022683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2475037922022683"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2022.100018","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombin generation and implications for hemophilia therapies: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2022.100018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"100018"}}